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Background: Semi-synthetic artemisinin derivatives are powerful peroxidic drugs in artemisinin-based combination
therapy (ACT) recommended as first-line treatment of Plasmodium falciparum malaria in disease-endemic countries.
Studies by Eckstein-Ludwig and co-workers showed both thapsigargin and artemisinin specifically inhibit the
sarcoplasmic reticulum Ca2+−ATPase of Plasmodium falciparum (PfATP6). In the present study the type of interaction
between thapsigargin and artemisinin derivatives as well as the ozonide OZ277 (RBx11160 or arterolane) was
evaluated in parasite cultures. The latter compound is an adamantane-based peroxide and the first fully synthetic
clinical candidate recently registered in India by Ranbaxy Laboratories Ltd. for anti-malarial combination therapy.
Methods: Drug interaction studies were performed using a previously described fixed ratio method and
anti-malarial activity measured using the [3H] hypoxanthine incorporation assay.
Results: The sum 50% and 90% fractional inhibitory concentration (
P
FIC50, 90) of the interaction of thapsigargin
with OZ277, artemether or artesunate, against NF54 and K1 strains of P. falciparum ranged from 0.9 to 1.4.
Conclusion: The interaction of thapsigargin with OZ277, artesunate or artemether was additive, data consistent
with previous observations indicating that activity of anti-malarial peroxides does not derive from reversible
interactions with parasite targets.
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Artemisinin is a sesquiterpene lactone isolated from Ar-
temisia annua. Semi-synthetic artemisinin derivatives
are important endoperoxides in artemisinin-based com-
bination therapy (ACT) recommended as first-line treat-
ment of Plasmodium falciparum malaria in endemic
countries. Despite their importance, the precise mechan-
ism of action of this compound class is still under de-
bate. The dominating view for all the peroxides
(artemisinin derivatives and synthetic peroxides such as
ozonides) is that they undergo reductive activation of* Correspondence: sergio.wittlin@unibas.ch
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reproduction in any medium, provided the orthe peroxide in the presence of ferrous iron released
upon haemoglobin digestion within the parasite food
vacuole [1]. This forms carbon centred radicals, which
then alkylate key parasite proteins like haem and
membrane-associated parasite proteins [2], one of which
is the translationally controlled tumour protein
(PfTCTP) [3] and another could be PfATP6, a SERCA-
type Ca2+-ATPase [4]. Studies by Eckstein-Ludwig and
co-workers showed that thapsigargin and artemisinin
specifically inhibit PfATP6 with Ki values (half-max-
imum inhibition constants) of 146 and 162 nM, respect-
ively [4]. In addition, artemisinin was shown to have a
similar distribution in parasites when compared with
thapsigargin, a specific inhibitor of PfATP6. Also, inter-
action between thapsigargin and artemisinin resulted in
antagonism in cultured parasites. Interestingly, Crespoal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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epoxy-endoperoxides showed additive activity when used
in combination with thapsigargin [5]. In the present
study the type of interaction between thapsigargin and
artemisinin derivatives as well as the ozonide OZ277
(RBx11160 or arterolane) [6,7] was evaluated in parasite
cultures for the first time. A previous study to under-
stand the mechanism(s) of action of OZ277 revealed that
it inhibits PfATP6 with a Ki value of 7,700 nM; thus it is
a much weaker inhibitor than artemisinin [8]. The study
further showed that a fluorescent derivative of OZ277
displayed patterns of subcellular distribution different
from that of artemisinin [8]. In order to shed more light
on the mechanism of action of peroxidic anti-malarials
vis à vis their interaction with PfATP6 in cultured para-
sites, the interaction of thapsigargin with OZ277 or the
semi-synthetic artemisinin derivatives (artesunate and
artemether) was evaluated in Plasmodium falciparum
K1 and NF54 strains.Methods
Compounds
The compounds used in this study were from the follow-
ing sources: OZ277 tosylate (J L Vennerstrom, Nebraska,
USA), artemether (Kunming Pharmaceuticals Corp, China),
artesunate (Roche, Basel, Switzerland) and thapsigargin
(Sigma, USA).Table 1 In vitro anti-malarial activity of semi-synthetic
artemisinins, synthetic OZ277 and thapsigargin against
Plasmodium falciparum K1 and NF54 strains
Compounds Inhibitory concentrations (ng/ml)
+P. falciparum K1 +P. falciparum NF54
(Mean ± SE) (Mean ± SE)
IC50 IC90 IC50 IC90
Artesunate 0.60 ± 0.18 1.8 ± 0.1 0.98 ± 0.48 1.9 ± 1.1
Artemether 0.45 ± 0.28 0.80 ± 0.34 0.49 ± 0.18 0.98 ± 0.27
OZ277 0.17 ± 0.03 0.42 ± 0.11 0.82 ± 0.09 1.6 ± 0.4
Thapsigargin 1612 ± 140 6850 ± 730 1940 ± 433 7455 ± 2307
+Data was obtained from three independent experiments. SE = standard error.In vitro anti-malarial activity
Plasmodium falciparum strains NF54 (sensitive to all
known anti-malarial drugs) and K1 (chloroquine/pyri-
methamine resistant) were cultivated and maintained in
continuous culture using standard techniques [9,10]. Ini-
tial concentrations for test compounds were 10 ng/ml
for artemether, artesunate, OZ277 and 20,000 ng/ml for
thapsigargin. Two-fold serial dilutions were done in
hypoxanthine-free culture medium in 96-well plates over
a 64-fold range, the lowest being 0.16 ng/ml and 313 ng/
ml for the anti-malarial drugs and thapsigargin respect-
ively. One hundred μl of an asynchronous parasite cul-
ture (0.3% parasitaemia and 2.5% haematocrit) was
added to the drug solutions (100 μl volume) in 96-well
plates. After 48-hr incubation, 0.5 microCi of [3H]hypo-
xanthine (Anawa, Zürich, Switzerland) in 50 μl of
medium was added to each well and plates were incu-
bated for an additional 24 hr. Parasites were harvested
onto glass-fibre filters and radioactivity was counted
using a Betaplate liquid scintillation counter (Wallac,
Zurich). The results were recorded as counts per minute
per well at each drug concentration and expressed as a
percentage of the untreated controls. Fifty percent in-
hibitory concentrations (IC50) were estimated by linear
interpolation [11].In vitro drug interactions
Drug interaction studies were performed using a modifica-
tion of the fixed ratios method [9,12]. Initially, the 50% in-
hibitory concentration (IC50) values of the individual test
compounds were determined. Subsequently, the anti-
malarial compounds and thapsigargin were diluted with
hypoxanthine-free culture medium to initial concentrations
of 10 times the predetermined IC50 and the solutions com-
bined in ratios of 1:3, 1:1, and 3:1. One hundred μl of the
individual test compounds and mixtures were then intro-
duced into the 96-well plates to give duplicate columns.
The IC50 of the test compounds alone and in combination
were determined as described above. For data interpret-
ation, the IC50 or IC90 of the drugs in combination were
expressed as fractions of the IC50 or IC90 of the individual
drugs. These fractions were called fractional inhibitory con-
centrations (FIC) for drug A and for drug B, respectively.
Interpretation of isobolograms
Isobolograms were constructed by plotting the FIC of drug
A (FICA) against the FIC of drug B (FICB) for each of the
three ratios, with concave curves indicating synergy, straight
lines indicating addition and convex curves indicating an-
tagonism. To obtain numeric values for the interactions,
results were expressed as the sum FICs (
P
FICs) of the
FICA and FICB. Cutoff ranges were determined by mixing
the same drug at various ratios and accounting for experi-
mental variation.
P






to 1.4 is additive,
P
FIC>1.4 is antagonistic. Mean
P
FICs
were used to classify the overall nature of the interaction.
Results and discussion
The susceptibility profile of OZ277, artesunate, artemether
and thapsigargin was determined against both chloroquine-
sensitive and -resistant strains of P. falciparum (NF54 and
K1) before embarking on the interaction studies. The two
groups of peroxides displayed potent anti-malarial activity
with IC50 and IC90 values ranging from 0.17 to 0.98 ng/ml
and 0.42 to 1.9 ng/ml respectively (Table 1). In contrast
Table 2 In vitro interaction of thapsigargin with OZ277 or semi-synthetic artemisinin derivatives against Plasmodium



























OZ277 K1 1.0 ± 0.0 1.0 ± 0.1 1.1 ± 0.0 1.1 ± 0.1 1.4 ± 0.1 1.4 ± 0.1 1.2 1.2
NF54 1.0 ± 0.1 1.0 ± 0.0 1.2 ± 0.1 0.9 ± 0.0 1.1 ± 0.1 0.9 ± 0.0 1.1 0.9
Artemether K1 1.2 ± 0.2 1.1 ± 0.0 1.1 ± 0.0 1.0 ± 0.1 1.1 ± 0.1 0.9 ± 0.1 1.1 1.0
NF54 1.1 ± 0.1 1.0 ± 0.1 0.9 ± 0.1 0.9 ± 0.0 1.2 ± 0.1 1.0 ± 0.0 1.1 1.0
Artesunate K1 1.2 ± 0.0 1.2 ± 0.0 1.2 ± 0.1 1.2 ± 0.2 1.3 ± 0.0 1.1 ± 0.1 1.2 1.2
NF54 1.1 ± 0.0 1.0 ± 0.0 1.1 ± 0.1 1.0 ± 0.1 1.0 ± 0.0 1.0 ± 0.1 1.1 1.0
+ Data was obtained from three independent experiments. * m
P
FICs was used to classify the overall nature of the interaction which appears to be additive in
this study.
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mately three to four log orders less potent (IC50 range of
1,600-1,900 ng/ml). Similar IC50 values for thapsigargin in
parasite culture have also been reported previously [4].
Subsequently, the in vitro interaction of OZ277 and
semi-synthetic artemisinin derivatives with thapsigargin
against P. falciparum strains with different degrees of
chloroquine sensitivity was evaluated. The employed
fixed ratio isobologram method was described earlier by
Fivelman and co-workers [12] and has been validated
using a series of in vitro control combination assays [9].
These control assays include: in vitro interaction of
artemether with pyrimethamine (proven antagonistic)
[13,14] and atovaquone with proguanil (proven syner-
gistic) [15,16]. Interactions data were analysed at the
IC50 and IC90 levels.
The sum 50% and 90% fractional inhibitory concentra-
tion (
P
FIC50, 90) of the interaction of thapsigargin with
OZ277, artemether or artesunate, against both strains of
P. falciparum ranged from 0.9 to 1.4 at the three ratios
(1:3, 1:1 and 3:1 tested, Table 2, Additional file 1). This
additive interaction is not unexpected based on the lack
of antagonism observed between either artemisinin or
OZ277 and their non-peroxide isosteres, data demon-
strating that the activity of these drugs does not derive
from reversible interactions with parasite targets [17].
Such additive interactions are also in line with data pub-
lished by Crespo and co-workers [5], who demonstrated
that artemisinin and two novel endoperoxides show
additive activity when used in combination with thapsi-
gargin. In contrast, data from Eckstein-Ludwig et al. [4]
showed that the combination of artemisinin and thapsi-
gargin was antagonistic (
P
FIC 1.5-5.0), which is possible
in a scenario in which artemisinin and thapsigargin inhibit
PfATP6 reversibly (non-covalent modification) [18].
Conclusion
The interaction of thapsigargin with OZ277, artesunate
or artemether was additive, data consistent with previousobservations indicating that activity of anti-malarial per-
oxides does not derive from reversible interactions with
parasite targets.
Additional file
Additional file 1: Representative isobolograms of in vitro interactions
of thapsigargin with OZ277 or semi-synthetic artemisinins against
Plasmodium falciparum.
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